

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wanda A. Cromlish, et al



Serial No. 09/731,632

Filed: November 20, 2000

For: HUMAN CYCLOOXYGENASE-2 CDNA AND ASSAYS
FOR EVALUATING CYCLOOXYGENASE-2 ACTIVITYArt Unit: 1652Examiner: Rao, Manjunath N.Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SEP - 3 2004

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Ante Ramp Date August 30 2004

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☒ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Curtis C. Panzer

Attorney _____ For Applicant(s)

Reg. No. 33,752

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3199

Date: August 30, 2004

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number 09/731,632
 Filing Date November 20, 2000
 First Named Inventor Wanda A. Cromlish, et al
 Group Art Unit 1652
 Examiner Name Rao, Manjunath N.
 Attorney Docket Number 189061AR

SEP - 3 2004
 TECH CENTER 1600/2300

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Jeanette A. M. Maier, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 265, pp. 10805-10808 (1990)
		Timothy Hla, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 266, pp. 24059-24063 (1991)
		Timothy Hla, et al., <u>PROC. NATL. ACAD. SCI. USA</u> , Vol. 89, pp. 7384-7388 (1992)
		Funk, et al., <u>FASEB JOUR.</u> , Vol. 5, pp. 2304-2312 (1991)
		Rodan, et al., <u>JOURNAL OF BONE AND MINERAL RESEARCH</u> , Vol. 1, No. 2, pp. 213-220, (1986)
		Patel, et al., <u>VIROLOGY</u> , Vol. 149, No. 2, pp. 174-189 (1986)
		Sato, et al., <u>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</u> , Vol. 141, No. 1, pp. 285-291 (1986)
		Zhang, et al., <u>PROSTAGLANDINS LEUKOTRIENE AND ESSENTIAL FATTY ACIDS</u> , Vol. 49, pp. 521-526 (1993)
		O'Banion, et al., <u>PROC. NATL. ACAD. SCI. USA</u> , Vol. 89, pp. 4888-4892 (1992)
		Wiesenberg-Boettcher, et al., <u>DRUGS EXPTL. CLIN. RES.</u> , XV (11/12), pp. 501-509 (1989)
		Tsuji, et al., <u>CHEM. PHARM. BULL.</u> , Vol. 40, No. 9, pp. 2399-2409 (1992)
		Gans, et al., <u>THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS</u> , Vol. 254, No. 1, pp. 180-187 (1990)
		Hoff, et al., <u>FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES</u> , Vol. 320, No. 1, pp. 38-42 (1993)
		ACS 1994 Registry Number 80937-31-1, Flosulide
		David A. Jones, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 268, No. 12, pp. 9049-9054 (1993)

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

of

3

COMPLETE IF KNOWN

Application Number 09/731,632
 Filing Date November 20, 2000
 First Named Inventor Wanda A. Cromlish, et al
 Group Art Unit 1652
 Examiner Name Rao, Manjunath N.
 Attorney Docket Number 18906IAR

NON PATENT LITERATURE DOCUMENTS

SEP - 3 2004
 TECH CENTER 1600/2900

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		P. Ryseck, et al., <u>CELL GROWTH & DIFFERENTIATION</u> , Vol. 3, pp. 443-450 (1992)
		Timothy Hla, et al., <u>PROC. NATL. ACAD. SCI. USA</u> , Vol. 89, pp. 7384-7388 (1992)
		Weilin Xie, et al., <u>DRUG DEVELOPMENT RESEARCH</u> , Vol. 25, pp. 249-265 (1992)
		Jean Sirois, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 267, No. 9, pp. 6382-6388 (1992)
		Bradley S. Fletcher, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 267, No. 7, pp. 4338-4344 (1992)
		M. Kerry O'Banion, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 266, No. 34, pp. 23261-23267 (1991)
		Dean A. Kujubu, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 266, No. 20, pp. 12866-12872 (1991)
		Daniel L. Simmons, et al., <u>PROSTAGLANDINS, LEUKOTRIENES, LIPOXINS, AND PAF</u> , pp. 67-78 (1991)
		Weilin Xie, et al., <u>PROC. NATL. ACAD. SCI. USA</u> , Vol. 88, pp. 2692-2696 (1991)
		Glenn D. Rosen, et al., <u>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS</u> , Vol. 164, No. 3, pp. 1358-1365 (1989)
		David L. DeWitt, et al., <u>PROC. NATL. ACAD. SCI. USA</u> , Vol. 85, pp. 1412-1416 (1988)
		Chieko Yokoyama, et al., <u>FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES</u> , Vol. 231, No. 2, pp. 347-351 (1988)
		John P. Merlie, et al., <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , Vol. 263, No. 8, pp. 3550-3553 (1988)

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003